First Western Trust Bank Has $1.11 Million Position in Pfizer Inc. $PFE

First Western Trust Bank lifted its stake in Pfizer Inc. (NYSE:PFE) by 102.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,621 shares of the biopharmaceutical company’s stock after acquiring an additional 23,105 shares during the quarter. First Western Trust Bank’s holdings in Pfizer were worth $1,106,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. ABN Amro Investment Solutions acquired a new position in Pfizer in the 2nd quarter worth about $1,784,000. Cherokee Insurance Co bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $3,077,000. Candriam S.C.A. grew its stake in shares of Pfizer by 35.0% in the 2nd quarter. Candriam S.C.A. now owns 2,240,955 shares of the biopharmaceutical company’s stock valued at $54,323,000 after buying an additional 581,355 shares in the last quarter. Calamos Advisors LLC increased its holdings in Pfizer by 4.7% in the second quarter. Calamos Advisors LLC now owns 1,860,332 shares of the biopharmaceutical company’s stock worth $45,094,000 after buying an additional 83,966 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Pfizer by 4.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 864,174 shares of the biopharmaceutical company’s stock valued at $20,948,000 after acquiring an additional 38,639 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Stock Performance

PFE opened at $25.84 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s 50 day moving average price is $24.77 and its two-hundred day moving average price is $24.42. The firm has a market capitalization of $146.92 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.